Abstract

BackgroundIn head and neck cancer little is known about the kinetics of osteopontin (OPN) expression after tumor resection. In this study we evaluated the time course of OPN plasma levels before and after surgery.MethodsBetween 2011 and 2013 41 consecutive head and neck cancer patients were enrolled in a prospective study (group A). At different time points plasma samples were collected: T0) before, T1) 1 day, T2) 1 week and T3) 4 weeks after surgery. Osteopontin and TGFβ1 plasma concentrations were measured with a commercial ELISA system. Data were compared to 131 head and neck cancer patients treated with primary (n = 42) or postoperative radiotherapy (n = 89; group B1 and B2).ResultsA significant OPN increase was seen as early as 1 day after surgery (T0 to T1, p < 0.01). OPN levels decreased to base line 3-4 weeks after surgery. OPN values were correlated with postoperative TGFβ1 expression suggesting a relation to wound healing. Survival analysis showed a significant benefit for patients with lower OPN levels both in the primary and postoperative radiotherapy group (B1: 33 vs 11.5 months, p = 0.017, B2: median not reached vs 33.4, p = 0.031). TGFβ1 was also of prognostic significance in group B1 (33.0 vs 10.7 months, p = 0.003).ConclusionsPatients with head and neck cancer showed an increase in osteopontin plasma levels directly after surgery. Four weeks later OPN concentration decreased to pre-surgery levels. This long lasting increase was presumably associated to wound healing. Both pretherapeutic osteopontin and TGFβ1 had prognostic impact.

Highlights

  • In head and neck cancer little is known about the kinetics of osteopontin (OPN) expression after tumor resection

  • Patients from group B1 had more advanced tumor stages compared to groups compared to healthy controls (group A) and B2

  • Correlation of osteopontin and Transforming growth factor 1 (TGFβ1) with clinico-pathologic parameters There was no association of OPN and TGFβ1 with clinical tumor parameters

Read more

Summary

Introduction

In head and neck cancer little is known about the kinetics of osteopontin (OPN) expression after tumor resection. Head and neck cancer is one of the leading causes of cancer-related death with almost 60.000 new cases and 12.000 deaths per year in the US [1]. Standard treatment consists of primary surgery and adjuvant radiotherapy in locally advanced tumors. Concomitant chemo-radiotherapy is an alternative to surgery as a definitive treatment option [2]. Despite combined multimodality treatment survival rates at 5 years are still about 20–50% for stage III/IV tumors [3,4,5]. Identifying and targeting prognostic and predictive biomarkers is an attractive approach for the development of new treatment strategies

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call